Rate My Professor Nichola Cooper

Professor Nichola Cooper holds the position of Professor of Immune Haematology in the Department of Immunology and Inflammation, Faculty of Medicine, at Imperial College London. She is also an Honorary Consultant Haematologist at Imperial College Healthcare NHS Trust, where she leads the immune haematology service at Hammersmith Hospital, treating adults and children with conditions such as immune thrombocytopenia (ITP). Cooper obtained her MA from the University of Cambridge (1989-1992) and MBBS from the University of London (1992-1995), along with an MD from the University of London. She holds fellowships as FRCP and FRCPath. Her medical education took place at Cambridge University and Barts and the London School of Medicine and Dentistry. She completed her haematology training at University College Hospital and acquired further research experience at Cornell Medical College in New York and the Institute of Child Health, University College London. Registered as a consultant since 1996, Cooper directs a clinical and laboratory research group dedicated to immune haematology.

Her research specializations encompass idiopathic thrombocytopaenia, immune regulation of platelets and megakaryocytes, and broader immune-mediated haematological disorders including warm autoimmune haemolytic anaemia and Evans syndrome. Cooper has made significant contributions through key publications, such as the review 'State of the art – how I manage immune thrombocytopenia' in the British Journal of Haematology (2017), and correspondence in the New England Journal of Medicine on immune thrombocytopenia. Recent works include studies on rilzabrutinib efficacy in ITP patients (Blood, 2025) and the role of CD8+ T-cell clones in immune thrombocytopenia (Blood, 2023). She serves as a Trustee and Medical Advisor for the ITP Support Association, contributes to the NIHR Imperial Biomedical Research Centre immunology initiatives, and delivers lectures at international conferences on ITP management and novel therapies like fostamatinib and efgartigimod. Her efforts have advanced understanding and treatment options for autoimmune blood disorders.